A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome

Clinical trial NCT07181837 · RECRUITING

Trial details

NCT number: NCT07181837
Sponsor: MavriX Bio, LLC
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Angelman Syndrome

Start date: 2025-10-29
Primary completion: 2028-03-31
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.